Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling and marketing

General and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Progenity

Biora Therapeutics, Inc. engages in the provision of molecular and specialized diagnostic tests to clinicians. Its products include the Preparent Carrier Test, Innatal Prenatal Screen, Riscover Hereditary Cancer Test, and Resura Prenatal Test. The company was founded by Paul W. Hawran and Harry Stylli in 2010 and is headquartered in San Diego, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Women's health diagnostic firm, Progenity Inc (NASDAQ: PROG), will close its genetics laboratory as part of a strategic transformation that emphasizes its drug delivery technologies and therapeutics. Closing the lab and other "operational improvements" will allow the company to reduce annual the capital required for operations by approximately 70%, from more than $180 million to about $50 million in 2022.

Progenity to Close Genetic Test Services, Focus Shifts to Therapeutics

Progenity Inc (NASDAQ: PROG) has announced results from a preclinical study evaluating the delivery of PGN-001 (adalimumab liquid formulation) drug substance directly to the colon in an animal model of induced colitis. Adalimumab is the active ingredient used in AbbVie Inc's (NYSE: ABBV) flagship rheumatoid arthritis med, Humira.

Progenity's Targeted Delivery Of Adalimumab Shows Encouraging Action In Animal Models Induced With Colitis

Preclinical study shows therapeutic effect of locally delivered PGN-001 (adalimumab) drug substance Preclinical study shows therapeutic effect of locally delivered PGN-001 (adalimumab) drug substance

Progenity Provides Results from Key Study for Its Targeted Therapeutics Program

SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced the appointment of Sean Lavin, M.D. as Vice President, Business Development, Strategy, and Investor Relations. In this advisory role, Dr. Lavin will work with Progenity's senior management in the areas of strategy, business development, investor outreach, and shareholder value creation as the company transitions its focus towards biotechnology innovation. Dr. Lavin previously served as a Managing Director in equity research at BTIG and Lazard Capital Markets where he covered medical devices and diagnostics, and he currently runs his own firm, Alpha Lavin Advisors, which focuses on value creation within these sectors.

Sean Lavin, MD, Joins Progenity as Vice President, Business Development, Strategy, and Investor Relations

Two Abstracts Support Company's Targeted Therapeutics Program including the Drug Delivery System Two Abstracts Support Company's Targeted Therapeutics Program including the Drug Delivery System

Progenity Announces Poster Presentations at Digestive Disease Week 2021

Provides educational resources for both patients and healthcare providers Provides educational resources for both patients and healthcare providers

Progenity Joins Global Call to Raise Awareness of Preeclampsia in Pregnancy on World Preeclampsia Day – May 22nd

Progenity, Inc. (PROG) CEO Dr. Harry Stylli on Q1 2021 Results - Earnings Call Transcript

Reports revenues of $24.5 million in the first quarter of 2021, up 72% from prior quarter

Progenity Provides Corporate Update and Reports First Quarter 2021 Financial Results

Studies show location accuracy and tolerability of the novel oral Drug Delivery System (DDS) and point to a materially enhanced therapeutic/safety index for PGN-600 Studies show location accuracy and tolerability of the novel oral Drug Delivery System (DDS) and point to a materially enhanced therapeutic/safety index for PGN-600

Progenity Provides Preliminary Results from Key Studies for its Targeted Therapeutics Program

SAN DIEGO, May 11, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success developing and commercializing molecular testing products, announced today that it has received funding from the Crohn's & Colitis Foundation's IBD Ventures program to further develop Progenity's first-in-class oral Drug Delivery System (DDS) for delivery of targeted therapeutics for inflammatory bowel disease (IBD).

Progenity Receives Funding from Crohn's & Colitis Foundation IBD Ventures Fund to Develop Drug Delivery System for IBD

SAN DIEGO, May 06, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced that it will report first quarter 2021 financial results on Thursday, May 13, 2021 after the close of financial markets. Progenity's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.

Progenity to Report First Quarter 2021 Financial Results and Provide Corporate Update

Pre-validation study demonstrates commercial laboratory systems readiness; data show strong performance consistent with verification study Pre-validation study demonstrates commercial laboratory systems readiness; data show strong performance consistent with verification study

Progenity Provides Key Update Regarding its Preecludia™ Test for Preeclampsia

Progenity survey shows more women know their baby's “fruit size” than the key indicator of a common pregnancy complication

Survey Reveals Pregnant Women Lack Awareness About Preeclampsia, the #2 Cause of Maternal Death

Data demonstrate strong sensitivity and negative predictive value (NPV) Data demonstrate strong sensitivity and negative predictive value (NPV)

Progenity Presents Key Verification Study Data for Preecludia™ Preeclampsia Rule-out Test at the 2021 American College of Obstetricians and Gynecologists (ACOG) Annual Meeting

SAN DIEGO, April 26, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced that two abstracts related to Progenity's ingestible drug delivery technologies for the treatment of gastrointestinal disorders have been accepted for presentation at Digestive Disease Week® (DDW). The DDW Virtual Meeting, taking place May 21-23, 2021, is the world's premier meeting for physicians, researchers, and industry in the fields of gastroenterology, hepatology, endoscopy, and gastrointestinal surgery.

Progenity to Present Two Abstracts for Novel Ingestible Drug Delivery Technologies at Digestive Disease Week 2021

SAN DIEGO, April 08, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success developing and commercializing molecular testing products in women's health, will be presenting verification study data for its Preecludia™ rule-out test for preeclampsia at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting set to take place April 30 – May 2, 2021.

Progenity to Present Key Prospective Verification Study Data for its Preeclampsia Rule-Out Test at 2021 American College of Obstetricians and Gynecologists Annual Meeting

SAN DIEGO, April 06, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success developing and commercializing molecular testing products, today announced an agreement with Ionis Pharmaceuticals, the leader in RNA-targeted therapeutics, to evaluate the safety, tolerability and performance of Progenity's Oral Biotherapeutics Delivery System (OBDS) for oral systemic delivery of antisense oligonucleotides, developed and manufactured by Ionis.

Progenity and Ionis Pharmaceuticals Enter into Agreement to Evaluate Progenity's Ingestible Oral Biotherapeutics Technology for Delivery of Antisense Therapies

SAN DIEGO, March 27, 2021 /PRNewswire/ -- Johnson Fistel, LLP is investigating potential claims on behalf of Progenity, Inc. (NASDAQ: PROG) against certain of its officers and directors.  In June 2020, Progenity completed its initial public offering (the "IPO"), in which it approximately 6.7 million shares for $15.00 per share.

Johnson Fistel Investigates Progenity; Should Management be Held Accountable for Investors Losses?

Progenity, Inc. (PROG) CEO Dr. Harry Stylli on Q4 2020 Results - Earnings Call Transcript

Reports approximately 82,000 tests in the fourth quarter of 2020

Progenity Provides Corporate Updates and Reports Fourth Quarter and Full-Year 2020 Financial Results

New York, New York--(Newsfile Corp. - March 14, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Progenity, Inc. ("Silk Road" or the "Company") (NASDAQ: PROG). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Progenity and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Progenity, Inc. - PROG

SAN DIEGO, March 12, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced that it will report fourth quarter and full year 2020 financial results on Thursday, March 18, 2021 after the close of financial markets. Progenity's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.

Progenity to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update

SAN DIEGO, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced that it has entered into a definitive securities purchase agreement with two leading healthcare-focused investment funds for the sale of units consisting of shares of common stock and warrants to purchase common stock, as described below, in a private placement expected to result in gross proceeds to Progenity of approximately $25 million, before deducting placement agent commissions and other offering expenses.

Progenity Announces $25 Million Private Placement

SAN DIEGO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success developing and commercializing molecular testing products, today announced the initiation of a clinical study for their Drug Delivery System (DDS) capsule, an ingestible and self-guided drug delivery device. The study will evaluate the capsule's safety and tolerability in the gastrointestinal (GI) tract of Normal Healthy Volunteers (NHV). The study will also collect the first clinical data on the ability of the DDS to auto-locate and accurately deliver a payload to the colon, a key delivery site for the treatment of ulcerative colitis.

Progenity Initiates Safety and Tolerability Study of its Smart Capsule-Based Oral Drug Delivery System for GI Diseases

Progenity applauds focus on preeclampsia biomarkers as it prepares for the launch of the Preecludia™ test Progenity applauds focus on preeclampsia biomarkers as it prepares for the launch of the Preecludia™ test

News for Progenity Stock (PROG)